Retinal OCT Can Act as Prognostic Biomarker of Kidney Injury
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 11, 2023 -- Retinal optical coherence tomography (OCT) has potential to act as a noninvasive monitor and prognostic biomarker of kidney injury, according to a study published online Dec. 5 in Nature Communications.
Tariq E. Farrah, B.M., B.Sc., from the University of Edinburgh in the United Kingdom, and colleagues examined the potential of retinal OCT to track kidney injury, demonstrate treatment response, and predict outcomes in patients with predialysis chronic kidney disease (CKD), patients with kidney failure undergoing kidney transplantation, living kidney donors, and healthy volunteers.
The researchers identified similar retinal thinning and reduced macular volume in patients with CKD and those with a kidney transplant compared with healthy volunteers. The choroidal thinning seen in CKD was not seen in kidney transplant recipients whose choroids were similar to those of healthy volunteers. The degree of choroidal thinning in CKD was related to a reduced estimated glomerular filtration rate (eGFR) and the extent of kidney scarring. Choroidal thickness increased rapidly (~10 percent) following kidney transplantation and was maintained over one year; during the 12 months following kidney donation, gradual choroidal thinning was seen. Retinal and choroidal thickness was independently associated with eGFR decline over two years in patients with CKD.
"OCT metrics have already been incorporated into clinical trial outcome measures in multiple sclerosis and our data introduce the exciting possibility that these metrics might be included alongside eGFR and proteinuria to individualize cardiovascular risk and the risk of kidney disease progression in future trials in CKD," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
MONDAY, Oct. 28, 2024 -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for...
Comorbid Diabetes Increases Risk for Lower Extremity Amputation With Kidney Disease
FRIDAY, Oct. 18, 2024 -- Patients with comorbid diabetes have an elevated risk for lower extremity amputation (LEA) at all stages of chronic kidney disease (CKD) compared with...
Varying Dialysate Calcium Dosage Not Tied to Differences in All-Cause, Cardiovascular Mortality
FRIDAY, Oct. 18, 2024 -- There are no significant differences in all-cause or cardiovascular mortality with the prescription of dialysate calcium 1.50 versus 1.25 mmol/L for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.